dr. reddy's labs glp-1 receptor agonists weight management diabetes treatments Dr Reddy's on 'Obeda' launch: In step to democratize access to advanced therapy - Industry News

With the launch of Obeda®, India's first DCGI-approved semaglutide injection for Type 2 Diabetes, we are excited to support diabetes care in India with high-quality, accessible and affordable treatment. In a head-to-head

20.43

★★★★☆4.8 (126)

Dr. Reddy's Laboratories said on Friday that it will change the brand name of its semaglutide drug from "Olymviq" to "Olymra" after the Delhi High Court flagged phonetic and visual similarity with

23.88

★★★★★4.9 (98)

GLP-1 now available as tablets? Semaglutide will now be more accessible than ever as Dr. Reddy's gets nod to roll out generic oral semaglutide drug Meryl Dsouza shares all the details -

28.54

★★★★★5.0 (157)

Dr. Reddy's Laboratories Launches Obeda: A Breakthrough in Type 2 Diabetes Treatment, ETPharma

25.71

★★★★★4.7 (84)

GLP-1 now available as tablets? Semaglutide will now be more accessible than ever as Dr. Reddy's gets nod to roll out generic oral semaglutide drug, Meryl Dsouza shares all the details

28.34

★★★★★4.9 (203)

Generic Semaglutide of Dr Reddy's for Weight loss Treatment

28.74

★★★★★5.0 (176)

Dr Reddy's lines up biosimilars and GLP-1 launches to counter slowdown in US business. Move comes even as pricing pressure and regulatory complexity continue to weigh on global pharmaceutical markets. http://ow.ly/GPMa106tsXB

21.53

★★★★★4.8 (132)